OR-AIRSHIP
12.10.2021 15:02:08 CEST | Business Wire | Press release
Customer engagement company Airship today announced the line-up for Elevate 2021 , the second annual global virtual forum for marketers and mobile product owners, taking place October 27-28, 2021. Experts in mobile app experience and engagement will share how they’ve adapted and accelerated strategies to capture more value from mobile and drive competitive differentiation. Confirmed speakers include executives from Ace Hardware, The Allstate Corporation, Chipotle, CNBC, DAZN, Douglas, Disneyland Paris, GetPlus, Hawaiian Airlines, KeyBank, EnBW, Kilo Health, Onefootball, Ryde Technologies, Shell, Sirius XM, Synchrony, Ulta Beauty and YTL Communications — with more to come.
Registration for Elevate 2021 is free, with many more reasons to attend , and programming begins October 27 at 9 a.m. PDT for the Americas. Programming for APAC and EMEA starts October 28 at 8 a.m. IST/12:30 p.m. AEDT and 1 p.m. BST, respectively. In addition to keynotes, customer-led sessions and panels, small group breakout sessions will enable peer-to-peer discussions and networking opportunities. Elevate 2021 is hosted in partnership with AppsFlyer, Mixpanel and mParticle.
Leading technology analyst and visionary Benedict Evans, formerly of Andreessen Horowitz (a16z), will deliver the first featured keynote providing a macro view of all the ways that brand, retail, e-commerce, advertising and marketing are being overturned, and how mobile apps are becoming the universal touchpoint, fueling new models of customer experience that require brands to adapt to changing consumer behaviors. Following that, Jonathan Kay, co-founder and CEO of Apptopia, will share comprehensive data and insights into consumer app trends and how brands are driving app-first initiatives across industry verticals.
“Today, mobile apps are becoming a definitive destination for consumers and brands. This growing shift requires a new way of thinking and operating in order for brands to create and capture new levels of value,” said Brett Caine, CEO and president, Airship. “Elevate 2021’s unique blend of live, interactive content and virtual breakout rooms led by the world’s foremost experts, offers the perfect place for marketers, mobile product owners, developers and others to gain inspiration and knowledge from those who are successfully responding to what this shift means for their customers and brands.”
Airship in Independent Industry Analyst Evaluations
Airship was recently named a Leader in “The Forrester Wave™: Mobile Engagement Automation, Q3 2020 ,” receiving the highest score in the Strategy category and the second highest score in the Current Offering category.
Also, for the second consecutive year, Airship was positioned highest in its ability to execute and also furthest for its completeness of vision in Gartner’s 2020 Magic Quadrant for Mobile Marketing Platforms 1 , and received the highest Product Scores across all three Use Cases in Gartner’s 2020 Critical Capabilities for Mobile Marketing Platforms 2 , including the Acquisition, Engagement and Retention Use Cases.
1 Gartner “Magic Quadrant for Mobile Marketing Platforms ” by Mike McGuire, Anna Maria Virzi, Joseph Enever, October 26, 2020
2 Gartner “Critical Capabilities for Mobile Marketing Platforms ” by Mike McGuire, Anna Maria Virzi, Joseph Enever, October 29, 2020
Gartner Disclosure
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Airship
Thousands of the world’s leading brands rely on Airship to spark exceptional experiences with their customers through highly contextual and relevant interactions. Only Airship’s SaaS Customer Engagement Platform takes a mobile-first, data-led approach that enables brands to focus on individuals and their needs, rather than which marketing channels to use. Airship makes it much simpler and more effective to grow customer lifetime value in the omnichannel era.
With trillions of interactions intelligently orchestrated across mobile apps, mobile wallet, SMS, websites, and email, Airship optimizes the entire customer journey across all digital touchpoints at scale.
For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005465/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom